secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2022-11-17T23:59:59+00:00
Accession:  0001599298-22-000123
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics appoints Dr. Alessandra Cesano to Board of Directors, effective immediately
--------------------------------------------------------------------------------

- Dr. Cesano brings 25 years of oncology R&D experience; previously CMO at ESSA Pharma, NanoString, and Cleave Biosciences.
- She played an instrumental role in development and approval of Vectibix® (panitumumab) for colorectal cancer.
- Appointment aligns with Summit's plan to expand pipeline into oncology; she joins Compensation and Nominating Committees.
- Dr. Cesano also serves on the board of Puma Biotechnology (NASDAQ: PBYI) and is independent under Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929822000123/0001599298-22-000123-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929822000123/smmt-20221115.htm
  HTML page:      https://secwatch.observer/filing/0001599298-22-000123

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer